Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Multiple Myeloma 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Lymphoma 19Leukemia, Myeloid, Acute 18Myelodysplastic Syndromes 17Lymphoma, Non-Hodgkin 14Neoplasms, Plasma Cell 12Leukemia 12Neuroblastoma 11Leukemia, Lymphocytic, Chronic, B-Cell 11Lymphoma, Large B-Cell, Diffuse 9Hodgkin Disease 9Recurrence 7Melanoma 7Lymphoma, Mantle-Cell 7Hematologic Neoplasms 7Burkitt Lymphoma 7Sarcoma 6Ovarian Neoplasms 6Myeloproliferative Disorders 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Follicular 6Sarcoma, Ewing 5Neoplasm Metastasis 5Medulloblastoma 5Lymphoma, B-Cell, Marginal Zone 5Liver Neoplasms 5Wilms Tumor 4Rhabdomyosarcoma 4Retinoblastoma 4

Interventions

Cyclophosphamide 7fludarabine phosphate 6fludarabine 5Immunotherapy, Adoptive 3blinatumomab 2Cytarabine 2Azacitidine 2AP 1903 reagent 2venetoclax 1tisagenlecleucel 1ruxolitinib 1relugolix 1pulrodemstat besilate 1niraparib 1nilotinib 1enzalutamide 1Whole-Body Irradiation 1Tyrosine Kinase Inhibitors 1Rituximab 1Radiotherapy 1NKTR-255 1Melphalan 1Injections 1Imatinib Mesylate 1GNKG168 1Dasatinib 1Cetuximab 1CTL019 chimeric antigen receptor 1CD3 Complex 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasm, Residual × Melphalan × Clear all
NCT03494569 2026-03-18

Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

City of Hope Medical Center

Phase 1 Suspended
36 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡